| Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling. |
| |
| Device | RHA 2, RHA 3, RHA 4 |
|---|
| Generic Name | implant, dermal, for aesthetic use |
|---|
| Applicant |
| TEOXANE S.A. |
| rue de lyon 105 |
| geneva 1203 |
|
|---|
| PMA Number | P170002 |
|---|
| Date Received | 01/17/2017 |
|---|
| Decision Date | 10/19/2017 |
|---|
| Product Code |
LMH
|
| Docket Number | 17M-6232 |
|---|
| Notice Date | 10/23/2017 |
|---|
| Advisory Committee |
General & Plastic Surgery |
|---|
| Clinical Trials |
NCT02195427
|
|---|
| Expedited Review Granted? | No |
|---|
| Combination Product |
Yes
|
|---|
Approval Order Statement
Approval for the RH-2. The RHA 2 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. RHA 3 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. RHA 4 is indicated for injection into the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. |
| Approval Order |
Approval Order
|
| Summary |
Summary of Safety and Effectiveness |
| Labeling |
Labeling
Labeling Part 2
|
| Supplements: |
S002 S003 S004 S005 S006 S007 |
|
|
